Cardiol Therapeutics Secures $14.85 Million Bought-Deal Unit Financing
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cardiol Therapeutics ( (TSE:CRDL) ) has shared an announcement.
On February 2, 2026, Cardiol Therapeutics Inc. filed a Form 6-K in the United States to report that it had entered into an underwriting agreement and related warrant indenture, both dated January 23, 2026, supporting a bought-deal private placement financing. Under the agreement with Canaccord Genuity Corp. as sole underwriter and bookrunner, Cardiol is issuing 11,423,078 units at $1.30 per unit for gross proceeds of about $14.85 million, with each unit consisting of one common share and one-half of a warrant exercisable at $1.75 per share until January 23, 2028; the structure underscores the company’s ongoing reliance on Canadian-listed issuer financing exemptions and highlights its ability to access institutional capital through a guaranteed take-up, potentially strengthening its balance sheet and financial flexibility for future operations.
The most recent analyst rating on (TSE:CRDL) stock is a Hold with a C$1.00 price target. To see the full list of analyst forecasts on Cardiol Therapeutics stock, see the TSE:CRDL Stock Forecast page.
Spark’s Take on TSE:CRDL Stock
According to Spark, TipRanks’ AI Analyst, TSE:CRDL is a Neutral.
The score is held down primarily by very weak financial performance (pre-revenue profile, large ongoing losses, and substantial cash burn with shrinking equity), which increases financing and dilution risk despite low debt. Technicals provide only a modest offset due to improving short-term momentum, while valuation remains unattractive because the company is loss-making and offers no dividend support.
To see Spark’s full report on TSE:CRDL stock, click here.
More about Cardiol Therapeutics
Cardiol Therapeutics Inc., based in Oakville, Ontario, is a foreign private issuer listed in the United States and files its continuous disclosure under Form 40-F, positioning it within the North American life sciences and biotech capital markets and subject to Canadian and U.S. securities regulation.
YTD Price Performance: -2.29%
Average Trading Volume: 89,763
Technical Sentiment Signal: Sell
Current Market Cap: C$128M
For detailed information about CRDL stock, go to TipRanks’ Stock Analysis page.
